Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shandong Univ. HPSE compound 28: sourced facts only. name: "A 3-O-sulfated HS nonasaccharide 28 exhibited sub-micromolar HPSE inhibitory potency (IC50 = 0.761 μM) and is expected to minimize anticoagulant liabilities by lacking the canonical antithrombin-binding sequence." [PMID:42574901]; target: "A 3-O-sulfated HS nonasaccharide 28 exhibited sub-micromolar HPSE inhibitory potency (IC50 = 0.761 μM) and is expected to minimize anticoagulant liabilities by lacking the canonical antithrombin-binding sequence." [PMID:42574901]; developer: "State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China." [PMID:42574901]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shandong Univ. HPSE compound 28.